Your session is about to expire
← Back to Search
PLX3397 + Sirolimus for Sarcoma (PLX3397 Trial)
PLX3397 Trial Summary
This trial is testing a combination of drugs to see if they can effectively treat cancer while also being tolerable for patients. The first part of the trial establishes what dose is safe for patients, and the second part measures how well the combination works at that dose.
PLX3397 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPLX3397 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2012 Phase 2 trial • 20 Patients • NCT01217229PLX3397 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had up to 3 treatments for my MPNST, but no radiotherapy.I am not taking strong drugs that affect liver enzyme activity.I am 18 years old or older.I have been treated with specific cancer drugs targeting cell growth.My condition worsened after up to three standard treatments.I am HIV-positive on antiretroviral therapy or have chronic/acute hepatitis B or C.I have another cancer besides the one being treated, but it's approved by the trial sponsor.I have brain metastases that are causing symptoms.I haven't had major surgery or serious injury in the last 14 days and don't expect to need major surgery during the study.My side effects from previous treatments are mild, except for hair loss.My cancer is an advanced MPNST that cannot be surgically removed.My kidney function, measured by creatinine levels or clearance, is within the required range.My cancer type has been confirmed with a biopsy at a participating site.My cancer cannot be removed with surgery.I am able to care for myself and perform daily activities.I do not have any uncontrolled illnesses.I have not had radiation on 25% or more of my bone marrow or any radiation in the last 28 days.I haven't had chemotherapy or radiotherapy in the last 4 weeks and have recovered from any side effects.I cannot swallow pills or have issues that prevent proper medication absorption.I have severe heart issues, including heart failure or unstable heart disease.My sarcoma cannot be removed with surgery and is advanced.I am not on cancer treatment except for hormone therapy.I am allergic to medications similar to PLX3397 or sirolimus.I am currently taking warfarin.
- Group 1: Phase 2: PLX3397 and Sirolimus
- Group 2: Phase 1: PLX3397 and Sirolimus
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the highest participation rate for this medical experiment?
"This clinical trial requires 43 patients that meet the criteria of eligibility. Those able to take part can do so at Washington University in St. Louis, Missouri or University of Iowa in Iowa City, Iowa."
To what extent has PLX3397 been tested in scientific investigations?
"At present, there are 131 studies that focus on PLX3397. Of those trials, 14 have entered the third phase of clinical testing. Although much of this research is conducted in Cincinnati Ohio, 1148 other locations around the world are involved in these investigations."
How widely dispersed is the oversight of this trial?
"This research endeavor is recruiting volunteers from multiple medical institutions, such as Washington University in St. Louis (Missouri), the University of Iowa (Iowa City) and Columbia University (New york)."
What has the primary application of PLX3397 been in medical practice?
"Rejection of organ transplants, particularly those involving the liver, can often be treated with PLX3397. This medication has also been seen to ease functional limitation in kidneys and lungs."
Is there presently an opportunity to participate in this research study?
"This clinical trial is still open for recruitment, as per the medical data on clinicaltrials.gov. Initially posted on November 4th 2015, this study was last updated a mere two days ago in November 7th 2022."
Share this study with friends
Copy Link
Messenger